​
​

Keros Therapeutics Ownership | Who Owns Keros Therapeutics?

OverviewForecastRevenueFinancialsChart

Keros Therapeutics Ownership Summary

Keros Therapeutics is owned by 106.80% institutional investors, 5.43% insiders. Fmr is the largest institutional shareholder, holding 16.03% of KROS shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 2.43% of its assets in Keros Therapeutics shares.

KROS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKeros Therapeutics106.80%5.43%-12.23%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr4.72M16.03%$215.69M
Blackrock2.51M8.53%$114.86M
Vanguard group1.76M5.97%$80.30M
Alkeon capital management1.60M5.43%$73.07M
Darwin global management1.53M5.18%$68.77M
Orbimed advisors1.27M4.31%$57.98M
State street1.22M4.15%$55.82M
Price t rowe associates inc /md/1.19M4.03%$54.29M
Braidwell lp982.21K3.34%$44.89M
Jefferies financial group899.08K3.05%$41.09M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Darwin global management1.53M8.00%$68.77M
Adar1 capital management548.92K4.74%$25.09M
Tcg crossover management879.34K4.19%$40.19M
Opaleye management367.50K3.84%$16.79M
Blue owl capital lp157.63K2.00%$7.20M
Redmile group552.51K1.53%$25.25M
Braidwell lp982.21K1.41%$44.89M
Parkman healthcare partners198.63K1.22%$9.08M
Orbimed advisors1.27M1.15%$57.98M
Nantahala capital management378.81K1.01%$17.31M

Top Buyers

HolderShares% AssetsChange
Blackrock2.51M0.00%347.23K
Jefferies financial group899.08K0.44%265.41K
Goldman sachs group521.45K0.00%263.08K
Braidwell lp982.21K1.41%244.83K
Vanguard group1.76M0.00%211.36K

Top Sellers

HolderShares% AssetsChange
Point72 asset management370.35K0.04%-601.53K
State street1.22M0.00%-341.52K
Fmr4.72M0.01%-298.76K
Marshall wace, llp22.38K0.00%-250.59K
Franklin resources400.21K0.01%-231.84K

New Positions

HolderShares% AssetsChangeValue
Twinbeech capital lp48.99K0.04%48.99K$2.24M
Pfm health sciences, lp33.35K0.08%33.35K$1.52M
Assenagon asset management24.46K0.00%24.46K$1.12M
Artia global partners lp20.00K0.18%20.00K$914.00K
Squarepoint ops19.83K0.00%19.83K$906.32K

Sold Out

HolderChange
Principal securities-3.00
Nelson, van denburg & campbell wealth management group-4.00
Riggs asset managment-5.00
National bank of canada /fi/-10.00
Innealta capital-22.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20241521.33%31,449,8610.28%1060.99%85-10.53%408.11%
Mar 31, 202415023.97%31,360,89321.87%1041.38%9537.68%3719.35%
Dec 31, 202312114.15%25,732,58512.83%861.46%6938.00%316.90%
Sep 30, 2023106-13.82%22,805,5281.76%771.23%50-32.43%2916.00%
Jun 30, 2023123-6.11%22,410,6031.88%781.31%745.71%25-24.24%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp877.88K2.43%-3.12K
T. Rowe Price New Horizons877.88K2.43%-2.77K
Vanguard Total Stock Mkt Idx Inv953.11K2.35%-7.28K
iShares Russell 2000 ETF756.55K1.87%-1.69K
Fidelity Select Health Care650.00K1.80%-
Eventide Healthcare & Life Sciences I499.21K1.38%-180.79K
Vanguard Institutional Extnd Mkt Idx Tr482.15K1.34%56.10K
SPDR® S&P Biotech ETF453.41K1.26%5.02K
Fidelity Advisor Health Care I400.00K1.11%-
Fidelity Select Biotechnology387.88K1.08%88.76K

Recent Insider Transactions

DateNameRoleActivityValue
Aug 13, 2024GORDON CARL L-Sell$1.29M
Aug 13, 2024GORDON CARL L-Sell$9.71M
Aug 13, 2024ORBIMED ADVISORS LLC-Sell$9.71M
Aug 13, 2024ORBIMED ADVISORS LLC-Sell$1.29M
Nov 04, 2023Regnante Keith Chief Financial OfficerSell$1.81M

Insider Transactions Trends

DateBuySell
2024 Q3-4
2024 Q2--
2024 Q1--
2023 Q4-1
2023 Q2-5

KROS Ownership FAQ

Who Owns Keros Therapeutics?

Keros Therapeutics shareholders are primarily institutional investors at 106.80%, followed by 5.43% insiders and -12.23% retail investors. The average institutional ownership in Keros Therapeutics's industry, Biotech Stocks , is 44.97%, which Keros Therapeutics exceeds.

Who owns the most shares of Keros Therapeutics?

Keros Therapeutics’s largest shareholders are Fmr (4.72M shares, 16.03%), Blackrock (2.51M shares, 8.53%), and Vanguard group (1.76M shares, 5.97%). Together, they hold 30.53% of Keros Therapeutics’s total shares outstanding.

Does Blackrock own Keros Therapeutics?

Yes, BlackRock owns 8.53% of Keros Therapeutics, totaling 2.51M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 114.86M$. In the last quarter, BlackRock increased its holdings by 347.23K shares, a 16.03% change.

Who is Keros Therapeutics’s biggest shareholder by percentage of total assets invested?

Darwin global management is Keros Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.00% of its assets in 1.53M Keros Therapeutics shares, valued at 68.77M$.

Who is the top mutual fund holder of Keros Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Keros Therapeutics shares, with 2.43% of its total shares outstanding invested in 877.88K Keros Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools